Interstitial Cystitis Pipeline and Clinical Trials Assessment: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Imbrium Therapeutics, PureTech Health, Seikagaku Corporation, Ironwood Pharma, Integrative Therapeutics, Lipella Pharma, A

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Interstitial Cystitis pipeline constitutes 8+ key companies continuously working towards developing 10+ Interstitial Cystitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Interstitial Cystitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Cystitis Market.

The Interstitial Cystitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Interstitial Cystitis Pipeline Report: https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Interstitial Cystitis treatment therapies with a considerable amount of success over the years.
• Interstitial Cystitis companies working in the treatment market are Imbrium Therapeutics, PureTech Health, Seikagaku Corporation, Ironwood Pharmaceuticals, Inc., Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Vaneltix Pharma, Inc./Prevail Infoworks, Inc, and others, are developing therapies for the Interstitial Cystitis treatment
• Emerging Interstitial Cystitis therapies in the different phases of clinical trials are- Sunobinop, IMB 150, SI-722, IW-3300, Peppermint oil, Ferumoxytol, BOTOX, VNX001, and others are expected to have a significant impact on the Interstitial Cystitis market in the coming years.
• In March 2023, Ironwood Pharmaceuticals, Inc. has commenced a clinical trial named "Phase 2 Randomized, Double-blind, Placebo-controlled Study to Assess the Effectiveness, Safety, and Tolerability of Two Dose Levels of IW-3300 in Alleviating Bladder Pain in Individuals Diagnosed with Interstitial Cystitis/Bladder Pain Syndrome." The objective of this investigation is to determine the safety and efficacy of IW-3300 in treating interstitial cystitis/bladder pain syndrome (IC/BPS).
• In January 2022, Ironwood Pharmaceuticals, Inc. has launched a study titled "Safety and Tolerability Evaluation of Rectally Administered Single Ascending Doses of IW-3300 in Healthy Volunteers: A Phase 1 Placebo-controlled Trial." This initial human study aimed to assess the safety and tolerability of gradually increasing single doses of IW-3300. The experimental drug was administered rectally through a low-volume (20 mL) enema.

Interstitial Cystitis Overview
Interstitial Cystitis (IC), also known as Bladder Pain Syndrome (BPS), is a chronic condition characterized by inflammation and irritation of the tissues lining the wall of the bladder. It is a type of painful bladder syndrome that can lead to discomfort, pressure, and pain in the pelvic region. The exact cause of interstitial cystitis is not well understood, and it can be challenging to diagnose.

Get a Free Sample PDF Report to know more about Interstitial Cystitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Interstitial Cystitis Drugs Under Different Phases of Clinical Development Include:
• Sunobinop: Imbrium Therapeutics
• IMB 150: PureTech Health
• SI-722: Seikagaku Corporation
• IW-3300: Ironwood Pharmaceuticals, Inc.
• Peppermint oil: Integrative Therapeutics, Inc.
• Ferumoxytol: Lipella Pharmaceuticals, Inc.
• BOTOX: Allergan
• VNX001: Vaneltix Pharma, Inc./Prevail Infoworks, Inc

Interstitial Cystitis Route of Administration
Interstitial Cystitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Interstitial Cystitis Molecule Type
Interstitial Cystitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Interstitial Cystitis Pipeline Therapeutics Assessment
• Interstitial Cystitis Assessment by Product Type
• Interstitial Cystitis By Stage and Product Type
• Interstitial Cystitis Assessment by Route of Administration
• Interstitial Cystitis By Stage and Route of Administration
• Interstitial Cystitis Assessment by Molecule Type
• Interstitial Cystitis by Stage and Molecule Type

DelveInsight's Interstitial Cystitis Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Interstitial Cystitis product details are provided in the report. Download the Interstitial Cystitis pipeline report to learn more about the emerging Interstitial Cystitis therapies at:
https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Interstitial Cystitis Therapeutics Market include:
Key companies developing therapies for Interstitial Cystitis are - Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Ironwood Pharmaceuticals, Inc., Vaneltix Pharma, Inc., Prevail Infoworks, Inc., and others.

Interstitial Cystitis Pipeline Analysis:
The Interstitial Cystitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Cystitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Cystitis Treatment.
• Interstitial Cystitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Interstitial Cystitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Cystitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Interstitial Cystitis drugs and therapies-
https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Interstitial Cystitis Pipeline Market Drivers
• Increase in prevalence of Interstitial Cystitis, increase in Research and Development are some of the important factors that are fueling the Interstitial Cystitis Market.

Interstitial Cystitis Pipeline Market Barriers
• However, lack of approved drugs, lack of understanding about the cause of the disease and other factors are creating obstacles in the Interstitial Cystitis Market growth.

Scope of Interstitial Cystitis Pipeline Drug Insight
• Coverage: Global
• Key Interstitial Cystitis Companies: Imbrium Therapeutics, PureTech Health, Seikagaku Corporation, Ironwood Pharmaceuticals, Inc., Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Allergan, Vaneltix Pharma, Inc./Prevail Infoworks, Inc, and others
• Key Interstitial Cystitis Therapies: Sunobinop, IMB 150, SI-722, IW-3300, Peppermint oil, Ferumoxytol, BOTOX, VNX001, and others
• Interstitial Cystitis Therapeutic Assessment: Interstitial Cystitis current marketed and Interstitial Cystitis emerging therapies
• Interstitial Cystitis Market Dynamics: Interstitial Cystitis market drivers and Interstitial Cystitis market barriers

Request for Sample PDF Report for Interstitial Cystitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/interstitial-cystitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Interstitial Cystitis Report Introduction
2. Interstitial Cystitis Executive Summary
3. Interstitial Cystitis Overview
4. Interstitial Cystitis- Analytical Perspective In-depth Commercial Assessment
5. Interstitial Cystitis Pipeline Therapeutics
6. Interstitial Cystitis Late Stage Products (Phase II/III)
7. Interstitial Cystitis Mid Stage Products (Phase II)
8. Interstitial Cystitis Early Stage Products (Phase I)
9. Interstitial Cystitis Preclinical Stage Products
10. Interstitial Cystitis Therapeutics Assessment
11. Interstitial Cystitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Interstitial Cystitis Key Companies
14. Interstitial Cystitis Key Products
15. Interstitial Cystitis Unmet Needs
16 . Interstitial Cystitis Market Drivers and Barriers
17. Interstitial Cystitis Future Perspectives and Conclusion
18. Interstitial Cystitis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Interstitial Cystitis Market https://www.delveinsight.com/report-store/interstitial-cystitis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Interstitial Cystitis Epidemiology https://www.delveinsight.com/report-store/interstitial-cystitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Interstitial Cystitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.